BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27128693)

  • 21. Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).
    Palmerini E; Meazza C; Tamburini A; Bisogno G; Ferraresi V; Asaftei SD; Milano GM; Coccoli L; Manzitti C; Luksch R; Serra M; Gambarotti M; Donati DM; Scotlandi K; Bertulli R; Favre C; Longhi A; Abate ME; Perrotta S; Mascarin M; D'Angelo P; Cesari M; Staals EL; Marchesi E; Carretta E; Ibrahim T; Casali PG; Picci P; Fagioli F; Ferrari S
    Cancer; 2022 May; 128(10):1958-1966. PubMed ID: 35201621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
    Kang JM; Ju HY; Joo J; Sung JY; Park SY; Kim JH; Kang HG; Kwon M; Park M; Park HJ; Park BK
    Oncology; 2020; 98(2):81-90. PubMed ID: 31509843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proximal location in extremity long bones is a poor prognostic factor for osteosarcoma: A retrospective cohort study of 153 patients.
    Cates JM; Schoenecker JG
    Acta Oncol; 2016 Aug; 55(8):1036-9. PubMed ID: 27145235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?
    Tsuda Y; Tsoi K; Stevenson JD; Parry MC; Fujiwara T; Sumathi V; Jeys LM
    Clin Orthop Relat Res; 2020 Jun; 478(6):1190-1198. PubMed ID: 31904683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
    Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
    BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
    He L; Yang H; Huang J
    BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
    Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
    PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
    Berlanga P; CaƱete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
    Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
    Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,
    Bacci G; Ferrari S; Bertoni F; Picci P; Bacchini P; Longhi A; Donati D; Forni C; Campanacci L; Campanacci M
    Clin Orthop Relat Res; 2001 May; (386):186-96. PubMed ID: 11347833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma.
    Guo Z; Tang Y; Fu Y; Wang J
    Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.
    Jeys LM; Thorne CJ; Parry M; Gaston CL; Sumathi VP; Grimer JR
    Clin Orthop Relat Res; 2017 Mar; 475(3):842-850. PubMed ID: 27138473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis.
    Papakonstantinou E; Athanasiadou KI; Markozannes G; Tzotzola V; Bouka E; Baka M; Moschovi M; Polychronopoulou S; Hatzipantelis E; Galani V; Stefanaki K; Strantzia K; Vousvouki M; Kourou P; Magkou E; Nikita M; Zambakides C; Michelarakis J; Alexopoulou A; Gavra M; Malama A; Ntzani EE; Petridou ET
    Cancer Epidemiol; 2024 Jun; 90():102551. PubMed ID: 38447251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
    Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
    Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.
    Guo J; Reddick WE; Glass JO; Ji Q; Billups CA; Wu J; Hoffer FA; Kaste SC; Jenkins JJ; Ortega Flores XC; Quintana J; Villarroel M; Daw NC
    Cancer; 2012 Aug; 118(15):3776-85. PubMed ID: 22180392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
    Lewis VO; Raymond K; Mirza AN; Lin P; Yasko AW
    Clin Orthop Relat Res; 2006 Sep; 450():60-6. PubMed ID: 16906104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.